Q32 Bio reported additional Phase 2 data for bempikibart (bempi), helping the company strengthen its pitch for an alopecia areata treatment that targets IL-7 and TSLP signaling without JAK inhibitor-style risk signals. In Signal-AA part B, Q32 said the drug hit the primary goal, driving a sharp market reaction. The company reported hair regrowth measured by SALT-based thresholds after 36 weeks, and it said efficacy in the severe or very severe population exceeded what analysts expected. Q32 is positioning bempi as a potentially more durable alternative for patients who may face safety concerns with existing classes. In separate coverage, analysts highlighted how the latest readout compared with internal expectations and how Q32’s shares moved on the data, underscoring how sensitive investor sentiment is to incremental efficacy in dermatology immunology trials.